Besides PD-1, CTLA4, and LAG3, other immune checkpoint molecules like TIM3 and TIGIT have also been identified as potential tumor-agnostic targets for T-cell-mediated cancer immunotherapy [130,131,132]. This evidence concerns the gene PDCD1 and cancer.